Patents by Inventor Xiaobing Tian

Xiaobing Tian has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Prodigiosin Analogs And Methods Of Use
    Publication number: 20230312531
    Abstract: Prodigiosin analogs which reactivate the p53 pathway are provided, as well as compositions of these compounds, and methods for reactivation of the p53 pathway using these compounds are provided. The prodigiosin analogs may be used to treat cancer in which p53 mutation plays a role, including prostate cancer, breast cancer, kidney cancer, ovarian cancer, lymphoma, leukemia, and glioblastoma, among others.
    Type: Application
    Filed: December 7, 2022
    Publication date: October 5, 2023
    Inventors: Wafik S. El-Deiry, Xiaobing Tian
  • Prodigiosin analogs and methods of use
    Patent number: 11535608
    Abstract: Prodigiosin analogs which reactivate the p53 pathway are provided, as well as compositions of these compounds, and methods for reactivation of the p53 pathway using these compounds are provided. The prodigiosin analogs may be used to treat cancer in which p53 mutation plays a role, including prostate cancer, breast cancer, kidney cancer, ovarian cancer, lymphoma, leukemia, and glioblastoma, among others.
    Type: Grant
    Filed: October 21, 2020
    Date of Patent: December 27, 2022
    Assignee: Institute For Cancer Research
    Inventors: Wafik S. El-Deiry, Xiaobing Tian
  • Prodigiosin Analogs And Methods Of Use
    Publication number: 20220033382
    Abstract: Prodigiosin analogs which reactivate the p53 pathway are provided, as well as compositions of these compounds, and methods for reactivation of the p53 pathway using these compounds are provided. The prodigiosin analogs may be used to treat cancer in which p53 mutation plays a role, including prostate cancer, breast cancer, kidney cancer, ovarian cancer, lymphoma, leukemia, and glioblastoma, among others.
    Type: Application
    Filed: October 21, 2020
    Publication date: February 3, 2022
    Inventors: Wafik S. El-Deiry, Xiaobing Tian
  • Prodigiosin Analogs And Methods Of Use
    Publication number: 20210139465
    Abstract: Prodigiosin analogs which reactivate the p53 pathway are provided, as well as compositions of these compounds, and methods for reactivation of the p53 pathway using these compounds are provided. The prodigiosin analogs may be used to treat cancer in which p53 mutation plays a role, including prostate cancer, breast cancer, kidney cancer, ovarian cancer, lymphoma, leukemia, and glioblastoma, among others.
    Type: Application
    Filed: October 21, 2020
    Publication date: May 13, 2021
    Inventors: Wafik S. El-Deiry, Xiaobing Tian
  • Prodigiosin analogs and methods of use
    Patent number: 10870640
    Abstract: Prodigiosin analogs which reactivate the p53 pathway are provided, as well as compositions of these compounds, and methods for reactivation of the p53 pathway using these compounds are provided. The prodigiosin analogs may be used to treat cancer in which p53 mutation plays a role, including prostate cancer, breast cancer, kidney cancer, ovarian cancer, lymphoma, leukemia, and glioblastoma, among others.
    Type: Grant
    Filed: April 27, 2019
    Date of Patent: December 22, 2020
    Assignee: Institute For Cancer Research
    Inventors: Wafik S. El-Deiry, Xiaobing Tian
  • Prodigiosin analogs
    Patent number: 10654801
    Abstract: Prodigiosin analogs which reactivate the p53 pathway are provided, as well as compositions of these compounds, and methods for reactivation of the p53 pathway using these compounds are provided. The prodigiosin analogs may be used to treat cancer in which p53 mutation plays a role, including prostate cancer, breast cancer, kidney cancer, ovarian cancer, lymphoma, leukemia, and glioblastoma, among others.
    Type: Grant
    Filed: April 10, 2017
    Date of Patent: May 19, 2020
    Assignee: Institute For Cancer Research
    Inventors: Wafik S. El-Deiry, Xiaobing Tian, Shengliang Zhang
  • Prodigiosin Analogs And Methods Of Use
    Publication number: 20190375731
    Abstract: Prodigiosin analogs which reactivate the p53 pathway are provided, as well as compositions of these compounds, and methods for reactivation of the p53 pathway using these compounds are provided. The prodigiosin analogs may be used to treat cancer in which p53 mutation plays a role, including prostate cancer, breast cancer, kidney cancer, ovarian cancer, lymphoma, leukemia, and glioblastoma, among others.
    Type: Application
    Filed: April 27, 2019
    Publication date: December 12, 2019
    Inventors: Wafik S. El-Deiry, Xiaobing Tian
  • Prodigiosin Analogs
    Publication number: 20190119207
    Abstract: Prodigiosin analogs which reactivate the p53 pathway are provided, as well as compositions of these compounds, and methods for reactivation of the p53 pathway using these compounds are provided. The prodigiosin analogs may be used to treat cancer in which p53 mutation plays a role, including prostate cancer, breast cancer, kidney cancer, ovarian cancer, lymphoma, leukemia, and glioblastoma, among others.
    Type: Application
    Filed: April 10, 2017
    Publication date: April 25, 2019
    Inventors: Wafik S. El-Deiry, Xiaobing Tian, Shengliang Zhang